Pfizer Gross Margin 1986-2025 | PFE
Current and historical gross margin for Pfizer (PFE) over the last 10 years. The current gross profit margin for Pfizer as of June 30, 2025 is %.
| Pfizer Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2025-06-30 |
$63.83B |
$46.04B |
72.12% |
| 2025-03-31 |
$62.46B |
$45.15B |
72.28% |
| 2024-12-31 |
$63.63B |
$45.78B |
71.94% |
| 2024-09-30 |
$60.43B |
$40.93B |
67.73% |
| 2024-06-30 |
$56.22B |
$32.71B |
58.18% |
| 2024-03-31 |
$55.95B |
$32.50B |
58.09% |
| 2023-12-31 |
$59.55B |
$34.60B |
58.10% |
| 2023-09-30 |
$70.12B |
$43.08B |
61.44% |
| 2023-06-30 |
$79.27B |
$55.43B |
69.93% |
| 2023-03-31 |
$94.00B |
$64.75B |
68.89% |
| 2022-12-31 |
$101.18B |
$66.83B |
66.05% |
| 2022-09-30 |
$99.88B |
$65.45B |
65.53% |
| 2022-06-30 |
$101.28B |
$62.98B |
62.18% |
| 2022-03-31 |
$92.43B |
$55.79B |
60.35% |
| 2021-12-31 |
$81.29B |
$50.47B |
62.08% |
| 2021-09-30 |
$68.88B |
$45.08B |
65.45% |
| 2021-06-30 |
$55.12B |
$39.25B |
71.21% |
| 2021-03-31 |
$46.08B |
$35.38B |
76.78% |
| 2020-12-31 |
$41.65B |
$33.17B |
79.63% |
| 2020-09-30 |
$32.07B |
$25.85B |
80.62% |
| 2020-06-30 |
$34.47B |
$27.66B |
80.24% |
| 2020-03-31 |
$37.87B |
$30.31B |
80.03% |
| 2019-12-31 |
$40.91B |
$32.85B |
80.31% |
| 2019-09-30 |
$40.22B |
$31.79B |
79.05% |
| 2019-06-30 |
$40.84B |
$32.32B |
79.14% |
| 2019-03-31 |
$41.04B |
$32.18B |
78.42% |
| 2018-12-31 |
$40.83B |
$31.84B |
77.99% |
| 2018-09-30 |
$53.37B |
$41.94B |
78.59% |
| 2018-06-30 |
$53.24B |
$41.66B |
78.25% |
| 2018-03-31 |
$52.67B |
$41.35B |
78.50% |
| 2017-12-31 |
$52.55B |
$41.32B |
78.63% |
| 2017-09-30 |
$52.47B |
$41.29B |
78.68% |
| 2017-06-30 |
$52.35B |
$40.92B |
78.17% |
| 2017-03-31 |
$52.60B |
$40.66B |
77.30% |
| 2016-12-31 |
$52.82B |
$40.50B |
76.67% |
| 2016-09-30 |
$53.24B |
$40.72B |
76.48% |
| 2016-06-30 |
$52.29B |
$40.63B |
77.71% |
| 2016-03-31 |
$50.99B |
$40.33B |
79.09% |
| 2015-12-31 |
$48.85B |
$39.20B |
80.25% |
| 2015-09-30 |
$47.92B |
$38.98B |
81.35% |
| 2015-06-30 |
$48.20B |
$39.11B |
81.14% |
| 2015-03-31 |
$49.12B |
$39.75B |
80.92% |
| 2014-12-31 |
$49.61B |
$40.03B |
80.69% |
| 2014-09-30 |
$50.05B |
$40.38B |
80.68% |
| 2014-06-30 |
$50.33B |
$40.74B |
80.95% |
| 2014-03-31 |
$50.53B |
$41.16B |
81.46% |
| 2013-12-31 |
$51.58B |
$42.00B |
81.42% |
| 2013-09-30 |
$50.88B |
$41.69B |
81.95% |
| 2013-06-30 |
$51.19B |
$41.98B |
82.02% |
| 2013-03-31 |
$52.18B |
$42.84B |
82.10% |
| 2012-12-31 |
$54.66B |
$44.84B |
82.03% |
| 2012-09-30 |
$53.25B |
$43.99B |
82.61% |
| 2012-06-30 |
$56.90B |
$46.54B |
81.80% |
| 2012-03-31 |
$59.42B |
$47.87B |
80.56% |
| 2011-12-31 |
$61.04B |
$48.54B |
79.52% |
| 2011-09-30 |
$65.06B |
$51.27B |
78.81% |
| 2011-06-30 |
$64.44B |
$50.28B |
78.02% |
| 2011-03-31 |
$65.09B |
$50.81B |
78.06% |
| 2010-12-31 |
$65.17B |
$50.38B |
77.31% |
| 2010-09-30 |
$65.50B |
$50.32B |
76.82% |
| 2010-06-30 |
$61.13B |
$47.95B |
78.44% |
| 2010-03-31 |
$54.98B |
$43.73B |
79.53% |
| 2009-12-31 |
$49.27B |
$40.81B |
82.83% |
| 2009-09-30 |
$45.82B |
$39.15B |
85.45% |
| 2009-06-30 |
$46.17B |
$39.17B |
84.84% |
| 2009-03-31 |
$47.32B |
$39.78B |
84.08% |
| 2008-12-31 |
$48.30B |
$40.18B |
83.20% |
| 2008-09-30 |
$48.82B |
$39.80B |
81.52% |
| 2008-06-30 |
$48.84B |
$37.32B |
76.42% |
| 2008-03-31 |
$47.79B |
$36.45B |
76.28% |
| 2007-12-31 |
$48.42B |
$37.18B |
76.79% |
| 2007-09-30 |
$48.15B |
$37.32B |
77.51% |
| 2007-06-30 |
$48.44B |
$40.27B |
83.12% |
| 2007-03-31 |
$49.10B |
$41.24B |
84.00% |
| 2006-12-31 |
$48.37B |
$40.73B |
84.21% |
| 2006-09-30 |
$47.37B |
$40.28B |
85.03% |
| 2006-06-30 |
$46.35B |
$39.61B |
85.46% |
| 2006-03-31 |
$46.06B |
$39.35B |
85.43% |
| 2005-12-31 |
$47.41B |
$40.17B |
84.74% |
| 2005-09-30 |
$47.20B |
$40.43B |
85.66% |
| 2005-06-30 |
$48.77B |
$41.97B |
86.06% |
| 2005-03-31 |
$49.59B |
$42.80B |
86.31% |
| 2004-12-31 |
$48.99B |
$42.60B |
86.95% |
| 2004-09-30 |
$51.57B |
$43.12B |
83.61% |
| 2004-06-30 |
$51.09B |
$40.99B |
80.24% |
| 2004-03-31 |
$48.72B |
$38.39B |
78.81% |
| 2003-12-31 |
$44.74B |
$35.15B |
78.57% |
| 2003-09-30 |
$40.01B |
$32.54B |
81.33% |
| 2003-06-30 |
$35.66B |
$30.45B |
85.39% |
| 2003-03-31 |
$33.05B |
$28.92B |
87.50% |
| 2002-12-31 |
$32.29B |
$28.28B |
87.57% |
| 2002-09-30 |
$29.03B |
$25.89B |
89.18% |
| 2002-06-30 |
$28.86B |
$25.57B |
88.60% |
| 2002-03-31 |
$29.19B |
$25.65B |
87.87% |
| 2001-12-31 |
$29.02B |
$25.20B |
86.83% |
| 2001-09-30 |
$31.14B |
$25.52B |
81.95% |
| 2001-06-30 |
$30.47B |
$24.81B |
81.41% |
| 2001-03-31 |
$29.84B |
$24.14B |
80.92% |
| 2000-12-31 |
$29.41B |
$23.71B |
80.60% |
| 2000-09-30 |
$25.81B |
$21.48B |
83.21% |
| 2000-06-30 |
$21.99B |
$18.06B |
82.16% |
| 2000-03-31 |
$18.78B |
$15.56B |
82.86% |
| 1999-12-31 |
$15.54B |
$13.01B |
83.73% |
| 1999-09-30 |
$14.90B |
$12.58B |
84.43% |
| 1999-06-30 |
$14.90B |
$12.92B |
86.68% |
| 1999-03-31 |
$14.24B |
$12.14B |
85.28% |
| 1998-12-31 |
$13.35B |
$11.25B |
84.31% |
| 1998-09-30 |
$12.39B |
$10.11B |
81.61% |
| 1998-06-30 |
$11.71B |
$9.36B |
79.93% |
| 1998-03-31 |
$11.09B |
$8.82B |
79.49% |
| 1997-12-31 |
$10.74B |
$8.47B |
78.82% |
| 1997-09-30 |
$10.99B |
$8.77B |
79.79% |
| 1997-06-30 |
$11.14B |
$8.94B |
80.28% |
| 1997-03-31 |
$11.31B |
$9.10B |
80.48% |
| 1996-12-31 |
$11.31B |
$9.13B |
80.75% |
| 1996-09-30 |
$10.89B |
$8.86B |
81.37% |
| 1996-06-30 |
$10.63B |
$8.58B |
80.77% |
| 1996-03-31 |
$10.37B |
$8.24B |
79.49% |
| 1995-12-31 |
$10.02B |
$7.86B |
78.40% |
| 1995-09-30 |
$9.58B |
$7.34B |
76.63% |
| 1995-06-30 |
$9.11B |
$6.94B |
76.10% |
| 1995-03-31 |
$8.64B |
$6.60B |
76.40% |
| 1994-12-31 |
$8.28B |
$6.36B |
76.84% |
| 1994-09-30 |
$7.97B |
$6.12B |
76.83% |
| 1994-06-30 |
$7.77B |
$5.96B |
76.73% |
| 1994-03-31 |
$7.59B |
$5.81B |
76.55% |
| 1993-12-31 |
$7.48B |
$5.71B |
76.30% |
| 1993-09-30 |
$7.44B |
$5.62B |
75.54% |
| 1993-06-30 |
$7.39B |
$5.49B |
74.24% |
| 1993-03-31 |
$7.34B |
$5.38B |
73.27% |
| 1992-12-31 |
$7.23B |
$5.21B |
72.01% |
| 1992-09-30 |
$7.13B |
$5.02B |
70.35% |
| 1992-06-30 |
$7.08B |
$4.94B |
69.81% |
| 1992-03-31 |
$7.02B |
$4.85B |
69.19% |
| 1991-12-31 |
$6.95B |
$4.75B |
68.35% |
| 1991-09-30 |
$6.89B |
$4.64B |
67.45% |
| 1991-06-30 |
$6.76B |
$4.49B |
66.41% |
| 1991-03-31 |
$6.62B |
$4.34B |
65.51% |
| 1990-12-31 |
$6.41B |
$4.15B |
64.74% |
| 1990-09-30 |
$6.12B |
$3.96B |
64.69% |
| 1990-06-30 |
$5.91B |
$3.80B |
64.29% |
| 1990-03-31 |
$5.72B |
$3.65B |
63.90% |
| 1989-12-31 |
$5.67B |
$3.61B |
63.65% |
| 1989-09-30 |
$5.55B |
$3.52B |
63.45% |
| 1989-06-30 |
$5.49B |
$3.47B |
63.21% |
| 1989-03-31 |
$5.52B |
$3.48B |
62.95% |
| 1988-12-31 |
$5.39B |
$3.37B |
62.49% |
| 1988-09-30 |
$5.29B |
$3.28B |
62.04% |
| 1988-06-30 |
$5.21B |
$3.20B |
61.44% |
| 1988-03-31 |
$5.10B |
$3.14B |
61.49% |
| 1987-12-31 |
$4.92B |
$3.02B |
61.44% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
